^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + barecetamab (ISU104) (HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
928P - Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Published date:
09/14/2020
Excerpt:
ISU104 alone or combination with CET was safe and tolerable with encouraging clinical outcomes in R/M HNSCC treated with Comb. A phase II study of weekly ISU104 in combination with approved dose of CET is planned to further establish the clinical utility of ISU104.
Trial ID:
